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Introduction {#sec1}
============

Human embryonic stem cells (hESCs) are isolated from the inner cell mass of the blastocyst. During embryonic development cells of the inner cell mass differentiate to give rise to the entire embryo. *In vitro*, hESCs can be maintained in their pluripotent state using defined culture conditions, or exit pluripotency and differentiate into desired cell types upon receiving external developmental cues. Thus human pluripotent stem cells (hPSCs) have an important role in biomedical research and future regenerative medicine, especially with the ability to reprogram somatic cells into induced pluripotent stem cells ([@bib6]).

Several concerns regarding the genomic integrity of hPSCs *in vitro* and their tumorigenicity *in vivo* compromise their proper use. During prolonged culturing and culture adaptation, hPSCs tend to acquire various types of genetic aberrations. These acquired changes might alter the ability of hPSCs to self-renew, to respond to growth factors, and to differentiate, and they can lead to marked changes in their global gene expression ([@bib5], [@bib27], [@bib44]). The recurrent genetic abnormalities in hPSCs include gains of chromosomes 1, 12, 17, and X, and duplication of 20q11.21 and 12p13.31 ([@bib3], [@bib5], [@bib24], [@bib27], [@bib28], [@bib29], [@bib44]). However, the genes driving the positive selection of these alterations and the dramatic changes in the characteristics of the culture-adapted cells are largely unknown.

*In vivo* transplantation of hPSCs into immunodeficient mice results in tumors called teratomas, which consist of cells from all the three embryonic germ layers ([@bib5]). Although teratomas are benign tumors, genetic changes such as trisomy of chromosome 12 or duplication of the 20q11.21 region can enhance its aggressiveness ([@bib8], [@bib46]). Although these tumors are known to be polyclonal, composed of differentiated cells that originate from multiple undifferentiated progenies ([@bib9]), the mechanisms underlying tumor formation remain almost completely unknown.

In this study, we apply a genome-wide screen on hPSCs to identify genes that confer selective advantage under various selective pressures. By using the PiggyBac (PB) transposon system, we generated libraries of hESCs with altered gene expression levels on a genomic scale. Using these libraries, we defined the main pathways responsible for selection during chemical treatment, prolonged culturing, and teratoma formation.

Results {#sec2}
=======

Construction of PiggyBac Overexpression Libraries {#sec2.1}
-------------------------------------------------

In our screen, we used a PB transposon construct containing a puromycin resistance gene followed by the cytomegalovirus (CMV) enhancer and promoter sequences surrounded by PB inverted terminal repeat sequences ([Figure 1](#fig1){ref-type="fig"}A). This system has been shown to have no particular bias toward certain genomic locations and to leave no trace sequence after excision ([@bib14], [@bib15]). Upon co-transfection with PB transposase, this construct may integrate into the genome and activate nearby genes, or alternatively reduce gene expression if integrated intragenically or in regulatory elements. This was previously demonstrated by picking single colonies and analyzing the integration sites parallel to gene expression ([@bib14]). In the presence of transposase, we could achieve high integration efficiency and high number of individual colonies after selection ([Figures 1](#fig1){ref-type="fig"}B, [S1](#mmc1){ref-type="supplementary-material"}A, and S1B). To determine integration sites we used splinkerette PCR, a procedure that enables direct amplification of the integration sequences ([@bib38]) (see [Methods](#sec4){ref-type="sec"}).Figure 1Preparation and Characterization of the PB Libraries(A) Schematic representation of the constructs used to build the libraries, and the downstream experimental procedure.(B) MEF culture plates of 10 cm with ESCs electroporated with the transposon construct and with or without the transposase followed by puromycin selection. The plates were stained with methylene blue.(C) Location distribution of the transposon in different genomic features.(D) The genomic distribution of integration potential coverage. Each integration was expanded in size 25 kb to each direction, and then the coverage at each position in the genome was calculated.

We created two libraries, each containing ∼2.5×10^5^ individual integrations, named hereafter Library 1 and Library 2, suggesting a transposon integration within every ∼10 kb. As the integrated CMV promoter and enhancer are strong inducers of gene expression, able to activate genes at a distance of over 50 kb ([@bib14]), a given gene should be activated by five integrations on average.

To characterize the libraries, we extracted DNA from the total pool of cells in each library and added Illumina flow-cell-binding adaptors to the second splinkerette PCR primers. The PCR products were analyzed using Illumina next-generation sequencing, and the reads were mapped to the reference human genome. In both libraries, the integrations were distributed along the genome with a slight preference to transcribed regions, as was described previously ([@bib17]) ([Figure 1](#fig1){ref-type="fig"}C). The mean distance between intergenic integration to the nearest gene is ∼50 kb, a distance that allows activation by the CMV promoter ([Figure S1](#mmc1){ref-type="supplementary-material"}C). To gain insight into the comprehensiveness of our libraries, we utilized the fact that the CMV enhancer can activate genes from a distance. We simulated the effective region of each insertion by expanding the integration size by 25 kb to each direction *in silico*. We found that less than 8% of the genome, which consists mainly of heterochromatic regions, is not covered by any integration, whereas most of the genome is covered by two to eight integrations ([Figures 1](#fig1){ref-type="fig"}D, [S1](#mmc1){ref-type="supplementary-material"}D, and S1E). Overall, these results indicate that our overexpression libraries in hESCs have high genomic coverage.

Genes Involved in Resistance to PluriSIn-1 Drug Treatment {#sec2.2}
---------------------------------------------------------

We initially utilized the mutant libraries for the analysis of resistance of hESCs to drug treatment. We thus used PluriSIn-1, which is a small molecule inhibitor of stearoyl-CoA desaturase-1 (SCD1), a key enzyme in fatty acid metabolism, triggering apoptosis specifically in pluripotent cells ([@bib7]). PluriSIn-1 blocks the production of oleic acid (OA) and induces the endoplasmic reticulum (ER) unfolded protein response, leading to cell death by apoptosis ([@bib7]). This drug was proved to be highly efficient in eliminating pluripotent cells from cell cultures and preventing teratoma formation ([@bib7]).

To understand which mechanisms can confer resistance to PluriSIn-1, we treated our libraries with two rounds of 15 μM or 20 μM of PluriSIn-1. At the end of the experiment, all the samples were sequenced and analyzed by targeted DNA sequencing (DNA-seq) ([Table S1](#mmc1){ref-type="supplementary-material"}). Global analysis of the samples revealed strong selection to certain integration sites following the treatment ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). Unsupervised hierarchical clustering uncovered that in each library the treated samples clustered together and apart from the untreated control ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Principle component analysis (PCA) showed that the abundances of integrations before the treatments are relatively similar between the libraries, and different from those found after the treatments ([Figure 2](#fig2){ref-type="fig"}A). Next, we assembled a list of enriched integrations that could mediate the selection and defined the genes that might have been affected. We could assign genes for the majority of these integrations, although some integrations were located far from any known transcript and are probably passenger mutations ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Out of the hits, we found multiple integrations inside MED13A, a component of the mediator complex. MED13A was shown to be recruited to promoters by ATF6α, the master regulator of the ER unfolded protein response, to allow upregulation of stress response genes ([@bib37]). In addition, we detected integration upstream of GNPNAT1, a target of the transducer of the unfolded protein response signal XBP1 ([@bib42]). Intriguingly, 7 of the 27 significantly enriched integrations were related to the RAS signaling pathway including *MRAS* itself, guanine exchange factors (GEFs), and downstream targets ([Figures 2](#fig2){ref-type="fig"}B, 2C, and [S2](#mmc1){ref-type="supplementary-material"}E). Overall, these integrations seemed to have an activating effect on the RAS signaling pathway ([Table S2](#mmc1){ref-type="supplementary-material"}).Figure 2Activation of RAS Pathways Confers Resistance to PluriSIn-1(A) PCA analysis of the integration patterns of the different PluriSIn-1 treatments.(B) All the integrations that occupied more than 0.5% of the mapped reads at least at high concentrations of PluriSIn-1 and are more enriched in the 20-μM treatment than in the 15-μM treatment.(C) Schematic illustration of the RAS signaling pathway. Genes with detected integrations are marked in red.(D) Quantification of MRAS levels after transient overexpression.(E) Relative cell number after treatment with PluriSIn-1 in medium supplemented with different concentrations of OA. Data presented are an average of three biological repeats. p values were calculated with a one-tailed Student\'s t test, standard error is shown as error bars. The experiment was performed in feeder-free Matrigel-coated plates.

The initial screening with the libraries was performed on mouse embryonic fibroblast (MEF) feeder cells with ESC medium, which contains high levels of OA. However, elimination of hESCs grown on Matrigel-coated plates without MEFs and with the OA-poor mTeSR medium requires much lower concentration of PluriSIn-1 ([@bib7]). This high sensitivity of the cells can be reduced by supplementing OA to the medium ([@bib7]). To test whether RAS activation could confer resistance to PluriSIn-1, we cloned *MRAS* and transiently expressed it in hPSCs for 24 h ([Figure 2](#fig2){ref-type="fig"}D). Then, the cells were supplemented with different concentrations of OA and PluriSIn-1 for an additional 48 h followed by a viability test. Comparison of cells overexpressing *MRAS* to controls revealed greater resistance of *MRAS*-overexpressing cells to PluriSIn-1, when grown on mTeSR supplemented with 50 μM OA. This effect was dependent on the addition of OA to the medium, because it was not observed when supplementing the medium with 10 μM OA ([Figure 2](#fig2){ref-type="fig"}E). This significant resistance was observed even with transient transfection of the *MRAS* plasmid (∼30% of cells are transfected), which suggests a much greater effect than measured. This result suggests that RAS pathway activation leads to enhanced resistance to SCD1 inhibition. As the protective effects of *MRAS* occurred only in high concentration of OA in the medium, it is likely mediated by OA import into the cells. These conclusions are in line with the knowledge obtained from RAS-driven cancers ([@bib20], [@bib36], [@bib47]).

Genes Involved in Selection during Prolonged Culturing {#sec2.3}
------------------------------------------------------

To identify which genes are involved in the selection of hESCs during their culture adaptation, we grew both mutant libraries on plates with MEF feeder cells for 20 consecutive passages. Cells were collected every five passages and analyzed with high-throughput DNA-seq to determine the abundance of each of the mutant cells during the process of growth selection. The selection process affecting the cultured libraries was already evident from the change in the growth rate of cells ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3C). PCA analysis and unsupervised hierarchical clustering of the integration patterns in each passage showed that both libraries changed in a similar fashion during culturing ([Figures S3](#mmc1){ref-type="supplementary-material"}D and S3E). In addition, we observed a gradual increase in the frequency of certain integrations throughout passaging ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}F).Figure 3Changes in the PB Libraries during Long Culturing(A) The dynamics of the integration patterns during prolonged culturing of both libraries is shown as the percentage of each integration out of total mapped reads. Integrations that constitute at least 1% of the mapped reads at passage 5 to 20 are shown.(B) Dot plot of the entire map of integrations in chromosome 22 at different time points during culturing, with enlargement of the MYH9 locus. Each integration is plotted as a dot where the area represents the integration frequency out of the total mapped reads. Each horizontal line of dots corresponds to different passage. The color of each dot indicates the integration orientation.(C) Schematic representation of the RHO-ROCK pathway. Genes with detected integrations are marked in red.(D) Box plot depicting relative cell number after 2 days of treatment with increasing concentration of blebbistatin. A total of 10,000 cells were plated in Matrigel-coated 96-well plate with 6 repeats per concentration. Cell numbers were estimated using CellTiter-Glo. p values were calculated using a one-tailed Student\'s t test.(E) Quantification of the effect of ROCKi on proliferation. On the left graph 1,000 cells were plated in a 96-well plate with 6 repeats per treatment. The right panel shows a growth assay demonstrating the effect of ROCKi on cell proliferation with 50,000 cells that were plated in a 6-well dish. In all experiments, ROCKi was added for the first 24 h. Staining and quantification were performed using methylene blue. p values were calculated using a two-tailed Student\'s t test, standard error is shown as error bars.(F) Gene expression analysis of microarray of low- (p\<=25) and high-passage (p ≥ 50) hPSCs revealing changes in gene expression in RHO/ROCK pathway genes. p values were calculated using a two-tailed Student\'s t test.

The increased growth rate of the cells can be attributed to several mechanisms that may occur simultaneously in these heterogeneous cultures. Some mutations may enhance proliferation, some may reduce apoptosis, and some may suppress spontaneous differentiation. Many mutations can be harmful and thus are eliminated from the population. To understand the effect of each mutation that increases cell growth (abundance higher than 1% of the mapped reads at passage five or later), we identified the potentially affected genes ([Figure S3](#mmc1){ref-type="supplementary-material"}G). In our list, we found an integration upstream of the transcription factor SP3, which was shown to regulate expression levels of pluripotency master regulators NANOG and OCT4 in the mouse ([@bib32], [@bib48]); an activating integration near the insulin-like growth factor 1 receptor, which may confer enhanced growth and survival; and an integration in the first part of CDK13, which plays a role in regulating the cell cycle. In this gene list four genes were part of the RHO-Rho-associated kinase (ROCK) pathway ([Table S3](#mmc1){ref-type="supplementary-material"}). One of the most highly enriched integrations was within the non-muscle myosin II heavy chain II-a (*MYH9*) gene, which is an important component of actin-myosin motors ([Figure 3](#fig3){ref-type="fig"}B). This gene, which encodes an important part of the cytoskeleton, is involved in multiple processes, including cell motility and maintenance of cell shape ([@bib33]). Contractions are achieved by the binding of MYH9 to phosphorylated myosin light chain, which is activated by kinases such as the ROCK. ROCK is activated by phosphorylated RHO, which belongs to a family of GTPases ([@bib2]). These proteins are active when phosphorylated by GEF proteins ([Figure 3](#fig3){ref-type="fig"}C). In addition to *MYH9*, two RHO-GEF proteins had enriched integrations: *TIAM2* had integrations that were mapped to the beginning of the gene body and *SPATA13* had an activating integration upstream of the promoter. SPATA13 acts in multiple pathways and was shown to inhibit RHOA activity upon overexpression ([@bib10]). Additional integration mapped inside PAWR, a gene involved in actin-myosin contractility ([@bib39], [@bib40]) ([Figures 3](#fig3){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}H). hPSCs require a balance between the forces of the actin-myosin contractions and the opposing anchorage of the actin filaments through integrins and E-cadherins ([@bib31]). Altered balance leads to cell blebbing and apoptosis ([Figure 3](#fig3){ref-type="fig"}C).

Inhibition of MYH9 by high concentrations of blebbistatin (a nonmuscle myosin II heavy chain inhibitor) or small interfering RNA (siRNAs), was previously shown to increase cell survival and cloning efficiency of hESCs after colony dissociation ([@bib13]). Prolonged knockdown of MYH9 by siRNA was shown to suppress cell growth ([@bib13]). As the integration inside MYH9 is heterozygous, we hypothesized that partial MYH9 inhibition may be beneficial for cell growth. To test this hypothesis, we treated hESCs with increasing concentrations of blebbistatin for 2 days. Indeed, high concentrations of blebbistatin efficiently inhibit cell viability, However, low concentrations of blebbistatin significantly improve cell growth ([Figure 3](#fig3){ref-type="fig"}D).

Inhibition of ROCK using a specific inhibitor (Y27632, ROCKi) was shown to prevent apoptosis after dissociation into single cells and to increase colony formation capabilities ([@bib13], [@bib43]). To show that ROCK inhibition can increase cell growth, we plated cells with ROCKi for 24 h and then tested the effect of the ROCKi by maintaining or withdrawing the ROCKi supplement. We found that in addition to the enhancement of the cloning efficiency, inhibition of ROCK also provided a significant growth advantage ([Figure 3](#fig3){ref-type="fig"}E). These results were also seen after initial seeding of 48 h, ensuring that the effect is not on colony formation but on cell proliferation ([Figure S3](#mmc1){ref-type="supplementary-material"}I).

Our results demonstrate that genetic modifications in the RHO-ROCK pathway can affect cell survival and growth, mimicking the effect of inhibition of ROCK by small molecules. To further demonstrate this effect, we compared microarray gene expression levels of low- and high-passage hPSCs ([@bib30]). The euploidy of the cell lines was validated by e-karyotyping ([@bib45]). We discovered that activators of this pathway, such as *MYH9*, *RHO-A*, *RHO-B,* and *ROCK1*, are downregulated during culturing, whereas *RND2*, which is an inhibitor of ROCK1, becomes upregulated ([Figure 3](#fig3){ref-type="fig"}F). These results are not due to methylation differences between the groups ([Figure S4](#mmc1){ref-type="supplementary-material"}A). To further validate these results, we performed an additional analysis with more than 700 RNA sequencing datasets ([Figure S4](#mmc1){ref-type="supplementary-material"}B). As the vast majority of the studies does not report the passage number of the samples, we assessed the time in culture based on the expression of TSPYL5 and CAT, genes that are expressed in low-passage hPSCs and recurrently silenced by methylation during prolonged culturing ([@bib23], [@bib45]) ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C). Again, we detected reduction in the RHO-ROCK pathways signaling ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E). Overall, we show that the RHO-ROCK pathway can be altered during culturing, and this alteration may lead to enhanced cell survival.

Genes Involved in Selection during Teratoma Formation *In Vivo* {#sec2.4}
---------------------------------------------------------------

In addition to selection *in vitro*, we used our libraries to examine cell selection *in vivo*. In this assay, as a complementary approach, we also utilized a gene-trap mutant library constructed after enrichment for haploid hESCs ([@bib35]). The gene-trap construct inserts a splicing acceptor followed by a puromycin resistance gene and a poly(A) signal. This library targets expressed genes and creates a complete loss of function upon integration. To further characterize this library, we amplified the integration sites and analyzed them by high-throughput DNA-seq. As expected, integrations were enriched in expressed genes, and most of the affected genes contained more than one independent integration ([Figure 4](#fig4){ref-type="fig"}A). To study the mechanisms governing teratoma formation, we injected the overexpression libraries, as well as the haploid knockout library, under the skin of severe combined immunodeficient mice and obtained tumors composed of cells from the three germ layers after 8 weeks ([Figure S5](#mmc1){ref-type="supplementary-material"}A). From each teratoma, DNA was extracted from one to three distinct areas.Figure 4Selection of Specific Integrations during Teratoma Formation(A) Analysis of the gene-trap mutant library in haploid hESCs. The left bar plot shows the percentage of expressed genes fragments Per Kilobase of transcript per Million mapped reads (FPKM)\>0.5 with integrations. The right bar plot shows number of independent integrations in all the integration containing expressed genes.(B) Unsupervised hierarchical clustering of the different pieces (P) from the different teratomas (T). Also included are undifferentiated libraries as controls.(C) Recurrent integrations display higher coverage in the PB libraries, but not in the undifferentiated controls. In each group of samples, the integrations are divided according to the number of teratomas that each integration appears in (x axis). The y axis shows the mean percentage out of the total mapped reads of the integrations included in this group. Error bars represent standard error.(D and E) (D) Specific genomic regions are important for teratoma formation. Shown are scores of 30,000-bp windows along the genome. The red dashed line marks the score that is 2-fold higher than the maximal score of the control group. The positions of the PI3K-AKT related genes are indicated in the graph. (E) Heatmap of the coverage of the genes shows that their scores are significantly higher in the teratoma samples than in the control. Highlighted are genes related to the PI3K-AKT and HIPPO pathways.(F) Schematic illustration of the PI3K-AKT and HIPPO pathways. Genes affected in the screen are marked with arrows. The direction of the arrow marks up- or down-regulation.(G) Cell viability curve after treating teratoma-derived cell line with the indicated drug for 96 h. The results are relative to control treated only with DMSO. Each time point is an average of three biological repeats. Error bars represent standard error.(H) Quantification of cell death by annexin V (An) and propidium iodide (PI) staining. Cells were treated with 5 μM VP for 24 h, 20 μM GSK690693 for 72 h, or with DMSO for 72 h. Data presented are an average of three biological repeats. p values were calculated with a two-tailed Student\'s t test. Error bars represent standard error. (I) Tumor weights after the indicated treatments.

Analysis of the integration patterns by unsupervised hierarchical clustering showed that the teratomas clustered distinctly from control undifferentiated libraries, and samples from the same library, as well as different pieces from the same teratoma, clustered together ([Figure 4](#fig4){ref-type="fig"}B). These results show that although each teratoma developed separately, some integrations were shared among the different tumors and even between the different libraries. The different pieces of each tumor clustered together, but with clear distance, implying both shared and separated selection mechanisms. Our results support previous reports showing that hPSC-induced teratomas are polyclonal tumors derived from multiple precursor cells ([@bib9]). However, our results demonstrate that genetic changes may affect the extent to which each cell may contribute to the teratoma mass.

To determine whether integrations shared between different teratoma samples may be relevant to the tumor development, we analyzed all the teratoma samples together. We also included six DNA-seq results of the undifferentiated libraries before injection as controls. We found that integrations that appeared in multiple control samples did not show an increase in the mean sequencing depth, implying that they were not positively selected. However, integrations that appeared in multiple teratoma samples had higher mean sequencing depth, pointing to their positive selection in the tumors ([Figure 4](#fig4){ref-type="fig"}C).

To find genomic loci that could be relevant to teratoma formation in the overexpression libraries, we scored windows of 30 kb along the genome (see [Methods](#sec4){ref-type="sec"}). As opposed to the control samples, wherein no significantly enriched regions were detected, we could detect multiple regions with high score in both libraries ([Figure 4](#fig4){ref-type="fig"}D). Interestingly, a few of these regions corresponded to regulators of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway, including key genes such as PTEN and PI3K ([Figures 4](#fig4){ref-type="fig"}D, [S5](#mmc1){ref-type="supplementary-material"}B, and S5C and [Table S4](#mmc1){ref-type="supplementary-material"}).

To identify genes whose knockout contributes to teratoma formation in the haploid library, we scored each gene both in the teratomas and in the control samples (see [Methods](#sec4){ref-type="sec"}). Among the genes with significantly higher scores in the teratomas, two genes were part of the PI3K-AKT pathway and four were in the HIPPO pathway ([Figure 4](#fig4){ref-type="fig"}E). The PI3K-AKT pathway and the HIPPO pathway cooperate to regulate cell proliferation, survival, and organ size, via a coordinated cross talk ([@bib16], [@bib21]) ([Figure 4](#fig4){ref-type="fig"}F). These results suggest a functional role of the PI3K-AKT and HIPPO signaling pathways during teratoma formation and growth.

To validate the involvement of HIPPO and AKT pathways in the formation of the tumor, we treated a teratoma-derived cell line with either a HIPPO-YAP inhibitor, verteporfin (VP) ([@bib19], [@bib26], [@bib41], [@bib49]), or with an AKT1-3 inhibitor, GSK690693 ([@bib1], [@bib12], [@bib25], [@bib34]). Indeed, inhibition of these pathways led to massive cell death ([Figures 4](#fig4){ref-type="fig"}G and 4H). The EC50 values of VP and GSK690693 are 0.58μM and 13.8μM, respectively, concentrations that are not lethal to all cell types ([@bib11], [@bib18]), suggesting that functional HIPPO and AKT signaling pathways are required for the survival of teratoma-derived cells. We then injected hESCs into immunodeficient mice, and 5 days after the injection, we started treating the mice three times a week with either HIPPO or AKT inhibitor. Analysis of the tumors after 6 weeks revealed a significant decrease in the weight of teratomas treated with either inhibitor ([Figure 4](#fig4){ref-type="fig"}I). The treatments did not affect the differentiation potential of the cells as we detected structures from the three embryonic germ layers in the treated teratomas ([Figure S5](#mmc1){ref-type="supplementary-material"}D). Overall, we demonstrated that these pathways are involved in the teratoma formation and growth.

Discussion {#sec3}
==========

hPSCs continuously acquire genomic changes during their growth in culture. These changes are the consequence of selection of specific clones that take over the culture. This may cause changes in the behavior of the cells, leading to false interpretation of experimental results and compromise future therapies. Genome-wide genetic screens enable the identification of genes that confer drug resistance and cellular selection *in vitro* and *in vivo*. PluriSIn-1 was suggested as a chemical compound that can eliminate pluripotent cells from differentiated cultures and reduce tumorigenic risks. Its specificity is achieved by the dependency of hPSCs on OA. Although it is highly specific to pluripotent cells, we show here that alteration in the RAS pathway can affect the sensitivity of the cells to this compound. These results strengthened the data obtained in RAS-driven cancers, which indicate reduced sensitivity of these tumors to SCD1 inhibitory treatments, due to increased import of lipid into the cells ([@bib20], [@bib36], [@bib47]). In addition, we suggest using growth medium completely lacking OA in future treatments of hPSCs with PluriSIn-1, which will render RAS-dependent resistance less effective.

By using the PB system, we sought to understand some of the molecular processes that take place during hPSC culture adaptation. We demonstrated the importance of the RHO-ROCK1 pathway in hPSCs survival. Although it is well established that ROCKi can be used during cell passaging to increase colony formation efficiency, we could show that inhibition of ROCK1 also increases hPSC growth. As this is the only pathway with multiple hits, we suggest that this is the main pathway involved in selection during culturing. We also showed that this pathway is altered in cultured cells at high passage, in the absence of any external genetic manipulation, supporting the importance of this pathway.

Our analysis emphasizes the strength of selection forces during growth in culture. In the long culturing experiment, already in a rather small number of passages (5 to 15 splits), few cells with advantageous integrations populated a high percentage of the culture. These rapid changes in the diversity of the population are a consequence of two factors: (1) the selective advantage of certain integrations and (2) the splitting process that drastically reduces the population size and eliminates cells with low representation in the cell culture (population bottleneck effect). Inhibition of the ROCK pathway (genetically or chemically) can alter the population bottleneck effect in both directions: increasing the genetic diversity because more cells survive the passage and reducing the genetic diversity because it allows harsher splitting. In addition, as we demonstrated, inhibition of the ROCK pathway affects the cell growth rate. Altogether, this demonstrates how quickly a mutation or chromosomal aberration can spread in the cell culture, emphasizing the importance of routine assays for genomic integrity.

Although we could detect significant hits, none of them mapped to the critical regions that drive the selection of the recurrently seen large chromosomal aberrations. This result may indicate that the selection advantage of our most significant hits is far greater than that of the genes that drive the selection of the common chromosomal aberrations. Alternatively, the positive selection of the recurrent large duplications may be generated by more than one gene, and thus cannot be detected in our assay.

Examination of the mechanisms leading to the formation of teratoma *in vivo* is extremely challenging. By following the positive selection in the tumor, we revealed the pathways that participate in tumor formation. We have shown the involvement of known oncogenes and pathways, especially the PI3K-AKT and HIPPO pathways in the formation and development of hPSC-induced teratomas. Previous experiments in mouse models have demonstrated that alterations in the PI3K-AKT pathway in the male primordial germ cells or in the female granulosa cells promote testicular or ovarian teratomas, respectively ([@bib4], [@bib22]). In line with these findings, our results show that the PI3K-AKT pathway is also involved in the development of human teratomas. Our results suggest that to reduce the risk of teratoma formation in future cell injection therapies, inhibition of PI3K-AKT and HIPPO pathway may be beneficial. Although the specific means of inhibition of these pathways should be calibrated, and the specific effects on the desired differentiated cell should be analyzed, these results suggest applicable approaches to reduce the risk of teratoma formation. Last, our results may have beneficial contribution to treating naturally occurring teratomas in humans, as they share induction mechanisms.

Limitations of the Study {#sec3.1}
------------------------

Genome-wide genetic libraries are a powerful tool to perform unbiased screens for genetic factors that regulate specific phenotypes. Transposable-elements-mediated genetic screen, as opposed to CRISPR-Cas9-based screens, does not rely on prior selection of the targets; however, the effects of the integrations are less predictable. In addition, in the system used in this study, each cell received more than one transposon on average, which complicates the process of identifying the driving genes. Last, in our system, integrations can cause both overexpression and downregulation, depending on the relative location and orientation of the integration from the gene. We chose not to validate the effect of each enriched integration, but rather to bioinformatically predict the effect on gene expression from the integration location and orientation relative to the nearby genes. This approach might introduce some noise to the experimental system. To overcome these difficulties, in each part of the study, we focused on pathways in which we can find integrations in multiple genes and directly validated the results by chemical or genetic approaches. Additional experiments using genome-edited cell lines or single-cell analysis would provide further support for the observed results.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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